Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine whether a new drug for schizophrenia is
better for the maintenance treatment than a standard drugs currently prescribed. The new
medication is called quetiapine and it will be compared with a standard medication called
haloperidol decanoate. The study will determine if quetiapine causes fewer problems than
haloperidol with side effects such as stiffness and restlessness and whether it costs the VA
more or less to treat patients with quetiapine. In addition, blood samples will be collected
every three months to determine if certain chemicals in the blood can influence the outcome
of the subjects' illness.
Phase:
N/A
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development